Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field

Nipro Managing Director Kiyotaka Yoshioka Nipro aims to grow its pharmaceutical segment into a 100 billion-yen business by FY2020. With the completion of the transfer of generics and long-listed products (LLPs) from Mitsubishi Tanabe Pharma, the firm has bolstered its...read more